| Field | Specification |
|---|---|
| Mfr No | |
| Activity | |
| Alternative Names | 2′-Deoxy-2′,2′-difluorocytidine hydrochloride; dFdC |
| Cas No. | |
| Form | Off-white powder |
| Molecular Weight | |
| Product Type | |
| Purity | |
| Shipping | |
| SMILES | |
| Solubility | May be dissolved in DMSO (20 mg/ml); or Water (25 mg/ml) |
| Source | Synthetic |
| Storage |
Gemcitabine HCl is a nucleoside analog used as an anticancer agent. It inhibits DNA polymerase and ribonucleotide reductase, leading to apoptosis. While primarily studied in oncology, its mechanisms of DNA synthesis inhibition and cell cycle arrest are relevant to neuroscience research, particularly in models of cytotoxic stress, DNA damage response, and neurodegeneration.
Classification: Danger. Hazard Statements: H360. Precautionary Statements: P201 - P202 - P280 - P308 + P313 - P405 - P501
Gemcitabine HCl (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-623)
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close
equivalents, or discuss custom synthesis with the right QC documentation (RUO).
2. Heinemann V., et al. (1995) Semin. Oncol. 22(4 Suppl 11):11.
3. Heinemann V., et al. (1992) Cancer Res. 52:533.
4. Pourquier P., et al. (2002) Clin. Cancer Res. 8:2499.
